Novel antifungal drug shows promise in some patients with Valley Fever

A subanalysis of a single-group, open-label, Phase IIb survey recovered that olorofim, a first-in-class orotomide antifungal cause that does not person U.S. FDA approval, showed efficacy successful patients with disseminated coccidioidomycosis (DCM), a uncommon complication of Valley Fever successful which the fungus spreads from the lungs to different parts of the body.